Next Article in Journal
Biochemical and Functional Characterization of Mouse Mammary Tumor Virus Full-Length Pr77Gag Expressed in Prokaryotic and Eukaryotic Cells
Next Article in Special Issue
Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development
Previous Article in Journal
Transcriptomic Analysis of the Campylobacter jejuni Response to T4-Like Phage NCTC 12673 Infection
Previous Article in Special Issue
Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIVSF162P3N-Infected Rhesus Macaques
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
Viruses 2018, 10(6), 333;

Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3000, Australia
CEA, Université Paris Sud 11, INSERM u1184, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Fontenay-aux-Roses 92265, France
Melbourne Sexual Health Clinic and Infectious Disease Department, Alfred Hospital, Monash University Central Clinical School, Melbourne, Victoria 3053, Australia
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The University of Melbourne, Parkville, Victoria 3052, Australia
Author to whom correspondence should be addressed.
Received: 4 May 2018 / Revised: 13 June 2018 / Accepted: 14 June 2018 / Published: 18 June 2018
(This article belongs to the Special Issue HIV Vaccines)
Full-Text   |   PDF [922 KB, uploaded 18 June 2018]   |  


Improved vaccine-mediated protection against HIV-1 requires a thorough understanding of the mode of HIV-1 transmission and how various immune responses control transmission. Cell-associated HIV-1 is infectious and contributes to HIV-1 transmission in humans. Non-human primate models of cell-associated SIV infection demonstrate that cell-associated SIV is more infectious than cell-free SIV. In a recently described chimeric simian–human immunodeficiency virus (SHIV) macaque model, it was demonstrated that an occult infection with cell-associated SHIV can be established that evades passive protection with a broadly neutralizing antibody (bnAb). Indeed, considerable in vitro data shows that bnAbs have less efficacy against cell-associated HIV-1 than cell-free HIV-1. Optimizing the protective capacity of immune responses such as bnAbs against cell-associated infections may be needed to maximize their protective efficacy. View Full-Text
Keywords: HIV-1; cell-associated virus; broadly neutralizing antibody; simian–human immunodeficiency virus HIV-1; cell-associated virus; broadly neutralizing antibody; simian–human immunodeficiency virus

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Parsons, M.S.; Le Grand, R.; Kent, S.J. Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Viruses 2018, 10, 333.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top